S-1/A: Applied DNA Sciences Eyes $12 Million Capital Raise Through Unit Offering

Applied DNA Sciences is seeking to raise capital through an offering of units, each consisting of common stock or pre-funded warrants, Series A and B warrants, and placement agent warrants.

Summary

• Applied DNA Sciences is offering 5,911,330 units, each consisting of one share of common stock (or a pre-funded warrant), one Series A warrant, and one Series B warrant, at an assumed public offering price of $2.03 per unit.
• The company is also offering pre-funded warrants in lieu of common stock to purchasers whose beneficial ownership would exceed 4.99% (or 9.99%) after the offering.
• Each pre-funded warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share.
• The Series A warrants will be exercisable upon stockholder approval at an exercise price to be determined, expiring five years from the approval date, while Series B warrants will be exercisable at an exercise price to be determined, expiring one year from the approval date.
• The offering is expected to terminate on June 30, 2024, and the company has engaged Craig-Hallum Capital Group LLC and Laidlaw & Company (UK) Ltd. as placement agents.
• The company estimates net proceeds of approximately $10.8 million from the offering, which will be used for the development of Therapeutic DNA Production and MDx Testing Services, as well as general corporate purposes.
• The company has received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement and must submit a plan by July 1, 2024, to regain compliance.
• A reverse stock split of one-for-twenty shares was effected on April 25, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
• The company's MDx Testing Services are currently subject to enforcement discretion by the FDA, but a final rule on LDTs may change this in the future.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively pursuing growth through a capital raise and has regained compliance with one Nasdaq requirement, it faces significant financial challenges, including substantial doubt about its ability to continue as a going concern and non-compliance with minimum stockholders' equity requirements. The risks associated with the company's business and the contingent nature of warrant exercises further temper the outlook.

Positives

• The offering aims to provide capital for the development of Therapeutic DNA Production and MDx Testing Services.
• The company has regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.
• The company's Linea DNA platform enables rapid, efficient, and large-scale cell-free manufacture of high-fidelity DNA sequences for use in the manufacturing of a broad range of nucleic acid-based therapeutics.

Negatives

• The company has a history of net losses and has an accumulated deficit of $308,255,808 as of March 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is not in compliance with the minimum stockholders equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market.
• The Series A and B warrants may have no value if stockholder approval is not obtained.
• The company expects future demand for COVID-19 testing to continue to be reduced and it may terminate COVID-19 testing services in the future.

Risks

• The company's limited revenue makes it difficult to evaluate future prospects.
• The company may require additional financing, which could dilute existing stockholders.
• The company's operating results could be adversely affected by a reduction in business with significant customers.
• The company's current emphasis on Therapeutic DNA Production Services may reduce its ability to maintain and expand its existing MDX Testing Services and DNA Tagging and Security Products and Services businesses.
• The company may be unable to consistently manufacture or source its products to the necessary specifications or in quantities necessary to meet demand on a timely basis and at acceptable performance and cost levels.
• The markets for drug and biologic candidates and synthetic DNA are very competitive.
• The company's intellectual property rights are valuable, and any inability to protect them could reduce the value of its products, services and brand.
• If the FDA were to begin to enforce regulation of laboratory-developed tests (LDTs), the company could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements in respect of MDx Testing Services.
• If the company fails to comply with laboratory licensing requirements, it could lose the ability to offer its MDx Testing Services or experience disruptions to its business.
• If the company fails to comply with healthcare laws, it could face substantial penalties and its business, operations and financial conditions could be adversely affected.
• There are a large number of shares of common stock underlying the company's outstanding options and warrants and the sale of these shares may depress the market price of its common stock and cause immediate and substantial dilution to its existing stockholders.
• The reverse stock split to regain compliance with Nasdaqs Minimum Bid Price Requirement, which was effected on Thursday, April 25, 2024, may adversely impact the market price of the company's common stock.
• The reverse stock split may decrease the liquidity of the shares of the company's common stock and the resulting market price of its common stock may not attract or satisfy the investing requirements of new investors, including institutional investors.
• The effective increase in the number of shares of the company's common stock available for issuance as a result of the reverse stock split may result in further dilution to its existing stockholders and have anti-takeover implications.

Future Outlook

The company intends to use the net proceeds from the sale of the securities for the further development of its Therapeutic DNA Production and MDx Testing Services, as well as general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement its business.

Industry Context

The company is positioning itself to capitalize on the rapid growth of mRNA therapies and the increasing demand for DNA-based therapeutics, which are areas of significant investment and development in the biotechnology industry.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• It mentions the number of gene, cell, and RNA therapies in development, citing ASGCT data, but does not compare Applied DNA Sciences' performance against specific competitors.
• The document does not provide enough information to make a detailed assessment of the results in the context of global benchmarks.

Stakeholder Impact

• Shareholders may experience dilution due to the offering and potential future equity issuances.
• The company's ability to fund its operations and execute its business plan depends on the success of the offering.
• The company's employees and customers may be affected by the company's financial stability and its ability to continue operations.

Next Steps

• The company must submit a plan to Nasdaq by July 1, 2024, to regain compliance with the Stockholders Equity Requirement.
• The company will hold a special meeting of shareholders to obtain Stockholder Approval for the exercise of the warrants.
• The company will continue to develop its Therapeutic DNA Production and MDx Testing Services.

Key Dates

Keywords

Therapeutic DNA Production Services, MDx Testing Services, Linea DNA, Warrants, Offering, Reverse Stock Split, Capital Raise, APDN, DNA